Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: A re-evaluation of P450 isoform selectivity

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 1, 2011, Pages 1-16

  Khojasteh, Siamak Cyrus ^a   Prabhu, Saileta ^a   Kenny, Jane R ^a   Halladay, Jason S ^a   Lu, Anthony Y H ^b  

^a GENENTECH INC   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYL 2 (1 PIPERIDINYL)PROPANE; 3 (2 METHYL 1H IMIDAZOL 1 YL)PYRIDINE; 3 BENZYL PHENOBARBITAL; 4 METHYLPYRAZOLE; ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; FURAFYLLINE; KETOCONAZOLE; METHOXSALEN; METHYLAMINE; MONTELUKAST; NICOTINE; PARACETAMOL; PHENOBARBITAL DERIVATIVE; PROPANE; PYRIDINE DERIVATIVE; QUINIDINE; SULFAPHENAZOLE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; LIVER MICROSOME; PHENOTYPE;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79951583350     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0024-2     Document Type: Article

References (193)

1. A Atkinson JR Kenny K Grime 2005 Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis Drug Metab Dispos 33 1637 1647 16049126 1:CAS:528:DC%2BD2MXhtFOru73O (Pubitemid 41539961)
2. SJ Baldwin JC Bloomer GJ Smith AD Ayrton SE Clarke RJ Chenery 1995 Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9 Xenobiotica 25 261 270 7618352 1:CAS:528:DyaK2MXmsVOju7k%3D
3. SJ Baldwin SE Clarke RJ Chenery 1999 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone Br J Clin Pharmacol 48 424 432 10510156 1:CAS:528:DyaK1MXmsFehsLY%3D (Pubitemid 29417728)
4. B Baune V Furlan AM Taburet R Farinotti 1999 Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes Drug Metab Dispos 27 565 568 10220483 1:CAS:528:DyaK1MXjtVansbw%3D (Pubitemid 29214466)
5. L Becquemont MA Le Bot C Riche C Funck-Brentano P Jaillon P Beaune 1998 Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man Pharmacogenetics 8 101 108 10022747 1:CAS:528:DyaK1cXjs1Ogs7g%3D (Pubitemid 28227317)
6. L Bell S Bickford PH Nguyen J Wang T He B Zhang Y Friche A Zimmerlin L Urban D Bojanic 2008 Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery J Biomol Screen 13 343 353 18474896 1:CAS:528:DC%2BD1cXotlCms7o%3D (Pubitemid 351793985)
7. TD Bjornsson JT Callaghan HJ Einolf V Fischer L Gan S Grimm J Kao SP King G Miwa L Ni G Kumar J McLeod RS Obach S Roberts A Roe A Shah F Snikeris JT Sullivan D Tweedie JM Vega J Walsh SA Wrighton 2003 The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab Dispos 31 815 832 12814957 1:CAS:528:DC%2BD3sXltFalu70%3D (Pubitemid 36759050)
8. JC Bloomer SJ Baldwin GJ Smith AD Ayrton SE Clarke RJ Chenery 1994 Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron Br J Clin Pharmacol 38 557 566 7888294 1:CAS:528:DyaK2MXivVKjsLc%3D (Pubitemid 24365864)
9. M Bourrié V Meunier Y Berger GJ Fabre 1996 Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes Pharmacol Exp Ther 277 321 332 (Pubitemid 27169077)
10. K Brøsen E Skjelbo BB Rasmussen HE Poulsen S Loft 1993 Fluvoxamine is a potent inhibitor of cytochrome P4501A2 Biochem Pharmacol 45 1211 1214 8466541 (Pubitemid 23098317)
11. SS Bun J Ciccolini H Bun C Aubert J Catalin 2003 Drug interactions of paclitaxel metabolism in human liver microsomes J Chemother 15 266 274 12868554 1:CAS:528:DC%2BD3sXmtFSqurg%3D (Pubitemid 36819316)
12. MD Burke S Thompson RJ Weaver CR Wolf RT Mayer 1994 Cytochrome P450 selectivities of alkoxyresorufin O-dealkylation in human and rat liver Biochem Pharmacol 48 923 936 8093105 1:CAS:528:DyaK2cXmvFGktLg%3D (Pubitemid 24285170)
13. X Cai RW Wang RW Edom DC Evans M Shou AD Rodrigues W Liu DC Dean TA Baillie 2004 Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes Drug Metab Dispos 32 584 586 15155548 1:CAS:528:DC%2BD2cXktlOgtr8%3D (Pubitemid 38668149)
14. WK Chan AB Delucchi 2000 Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4 Life Sci 67 3103 3112 11125847 1:CAS:528:DC%2BD3cXotlChur4%3D
15. TK Chang GF Weber CL Crespi DJ Waxman 1993 Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes Cancer Res 53 5629 5637 8242617 1:CAS:528:DyaK2cXpsV2mtA%3D%3D (Pubitemid 23360263)
16. TK Chang FJ Gonzalez DJ Waxman 1994 Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450 Arch Biochem Biophys 311 437 442 8203907 1:CAS:528:DyaK2cXlt1ynu7g%3D
17. TK Chang J Chen EY Yeung 2006 Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1 Toxicol Appl Pharmacol 213 18 26 16226778 1:CAS:528:DC%2BD28XktVGitbg%3D
18. A Chaudhary KL Willett 2006 Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort Toxicology 217 194 205 16271822 1:CAS:528:DC%2BD2MXhtlSjsrvK (Pubitemid 41773835)
19. K Chiba K Kobayashi K Manabe M Tani T Kamataki T Ishizaki 1993 Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation J Pharmacol Exp Ther 266 52 59 8331574 1:CAS:528:DyaK3sXlvFGjtLc%3D (Pubitemid 23315627)
20. M Chiba X Xu JA Nishime SK Balani JH Lin 1997 Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans Drug Metab Dispos 25 1022 1031 9311616 1:CAS:528:DyaK2sXmt1Wqsbs%3D (Pubitemid 27396488)
21. MS Ching CL Blake H Ghabrial SW Ellis MS Lennard GT Tucker RA Smallwood 1995 Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites Biochem Pharmacol 50 833 837 7575645 1:CAS:528: DyaK2MXotlOjurk%3D
22. J Chun UM Kent RM Moss LM Sayre PF Hollenberg 2000 Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl) propane Drug Metab Dispos 28 905 911 10901699 1:CAS:528:DC%2BD3cXlt1ahtro%3D (Pubitemid 30612608)
23. SE Clarke AD Ayrton RJ Chenery 1994 Characterization of the inhibition of P4501A2 by furafylline Xenobiotica 24 517 526 7975717 1:CAS:528: DyaK2cXkslejs7k%3D (Pubitemid 24207914)
24. LH Cohen MJ Remley D Raunig A Vaz 2003 In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates Drug Metab Dispos 31 1005 1015 12867489 1:CAS:528:DC%2BD3sXlvVOlsLg%3D (Pubitemid 36975672)
25. CL Crespi BW Penman 1997 Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions Adv Pharmacol 43 171 188 9342176 1:CAS:528:DyaK2sXnt1aksL0%3D
26. T Cresteil B Monsarrat P Paul Alvinerie JM Jean Marc Tréluyer I Isabel Vieira M Wright 1994 Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation Cancer Res 54 386 392 7903909 1:CAS:528:DyaK2cXhsFaqsb8%3D (Pubitemid 24053174)
27. HK Crewe MS Lennard GT Tucker FR Woods RE Haddock 1992 The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes Br J Clin Pharmacol 34 262 265 1389951 1:CAS:528:DyaK38Xmt1GktLs%3D
28. TT Denton X Zhang JR Cashman 2005 5-Substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6 J Med Chem 48 224 239 15634016 1:CAS:528:DC%2BD2cXhtVKktbfM (Pubitemid 40105261)
29. A Di Marco A Cellucci A Chaudhary M Fonsi R Laufer 2007 High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin Drug Metab Dispos 35 1737 1743 17600081 1:CAS:528:DC%2BD2sXhtFansbnP (Pubitemid 47481564)
30. L Di EH Kerns SQ Li GT Carter 2007 Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS Int J Pharm 335 1 11 17137735 1:CAS:528:DC%2BD2sXjs1Cns7w%3D (Pubitemid 46482859)
31. EA Dierks KR Stams HK Lim G Cornelius H Zhang SE Ball 2001 A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry Drug Metab Dispos 29 23 29 11124225 1:CAS:528:DC%2BD3MXpvFGq (Pubitemid 32041675)
32. SR Donahue DA Flockhart DR Abernethy JW Ko 1997 Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 Clin Pharmacol Ther 62 572 577 9390115 1:CAS:528:DyaK2sXnvVGrur8%3D (Pubitemid 28214936)
33. AJ Draper A Madan A Parkinson 1997 Inhibition of coumarin 7-hydroxylase activity in human liver microsomes Arch Biochem Biophys 341 47 61 9143352 1:CAS:528:DyaK2sXivVOis70%3D (Pubitemid 27198030)
34. VA Eagling JF Tjia DJ Back 1998 Differential specificity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes Br J Clin Pharmacol 45 107 114 9491822 1:CAS:528:DyaK1cXhtFSkt7c%3D (Pubitemid 28045676)
35. C Emoto S Murase Y Sawada BC Jones K Iwasaki 2003 In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole Drug Metab Pharmacokinet 18 287 295 15618748 1:CAS:528:DC%2BD2cXnt1yltw%3D%3D
36. DA Fairman C Collins S Chapple 2007 Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? Drug Metab Dispos 35 2159 2165 17823234 1:CAS:528: DC%2BD2sXhsVeiurzP (Pubitemid 350146201)
37. SR Faucette RL Hawke EL LeCluyse SS Shord B Yan RM Laethem CM Lindley 2000 Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity Drug Metab Dispos 28 1222 1230 10997944 1:CAS:528:DC%2BD3cXntVSlt70%3D
38. JL Fayer DM Petullo BJ Ring SA Wrighton KJ Ruterbories 2001 A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro Pharmacol Toxicol Methods 46 117 123 1:CAS:528:DC%2BD38XkslKhtrk%3D (Pubitemid 34685521)
39. FDA (2006) Guidance for industry: drug interaction studies-study, design, data analysis, and implication for dosing and labeling. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. Accessed on 10 January 2011
40. Finnström N, Bjelfman C, Söderström TG, Smith G, Egevad L, Norlén BJ, Wolf CR, Rane (2001) Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur J Clin Invest 31:880-886 (Pubitemid 34592088)
41. V Fischer L Johanson F Heitz R Tullman E Graham JP Baldeck WT Robinson 1999 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions Drug Metab Dispos 27 410 416 10064574 1:CAS:528:DyaK1MXhs12ktrs%3D (Pubitemid 29114251)
42. RS Foti JL Wahlstrom 2008 CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles Drug Metab Dispos 36 523 528 18048485 1:CAS:528:DC%2BD1cXjt1arsLg%3D (Pubitemid 351397977)
43. H Fujino I Yamada S Shimada M Hirano Y Tsunenari J Kojima 2003 Interaction between fibrates and statins-metabolic interactions with gemfibrozil Drug Metabol Drug Interact 19 161 176 14682608 (Pubitemid 37505160)
44. T Fukami M Nakajima H Sakai M Katoh T Yokoi 2007 CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline Drug Metab Dispos 35 335 339 17178771 1:CAS:528:DC%2BD2sXisl2itL0%3D (Pubitemid 46333918)
45. A Galetin SE Clarke JB Houston 2002 Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach Drug Metab Dispos 30 1512 1522 12433827 1:CAS:528:DC%2BD38XptVyisbY%3D (Pubitemid 35397061)
46. DM Gentile CH Verhoeven T Shimada DJ Back 1998 The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel J Pharmacol Exp Ther 287 975 982 9864282 1:CAS:528:DyaK1MXjvVSgug%3D%3D (Pubitemid 29131610)
47. G Gervasini C Martínez JA Agúndez FJ García-Gamito J Benítez 2001 Inhibition of cytochrome P450 2C9 activity in vitro by 5-hydroxytryptamine and adrenaline Pharmacogenetics 11 29 37 11207028 1:CAS:528:DC%2BD3MXhtFKhu78%3D (Pubitemid 32108659)
48. i values and impact of CYP3A5 expression Drug Metab Dispos 27 180 187 9929500 1:CAS:528:DyaK1MXhslanu7s%3D (Pubitemid 29072069)
49. Guengerich FP (2005) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry, 3rd edn. Kluwer/Plenum Publishers, New York 382
50. FP Guengerich 2006 Cytochrome P450s and Other Enzymes in Drug Metabolism and Toxicity AAPS J 8 E101 E111 16584116 1:CAS:528:DC%2BD28Xks1Kks70%3D
51. NT Ha-Duong S Dijols AC Macherey PM Dansette D Mansuy 2001 Inhibition by ticlopidine and its derivatives of human liver cytochrome p450. Mechanism-based inactivation of CYP 2C19 by ticlopidine Adv Exp Med Biol 500 145 148 11764927 1:CAS:528:DC%2BD38XjslGisr8%3D (Pubitemid 34106990)
52. SD Hall FP Guengerich RA Branch GR Wilkinson 1987 Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes J Pharmacol Exp Ther 240 216 222 2879902 1:CAS:528:DyaL2sXhsVyqs7w%3D (Pubitemid 17235440)
53. A Hemeryck C De Vriendt FM Belpaire 1999 Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes Eur J Clin Pharmacol 54 947 951 10192756 1:CAS:528:DyaK1MXhtFKns7o%3D (Pubitemid 29104416)
54. JJ Hermans HH Thijssen 1993 Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics Br J Pharmacol 110 482 490 8220911 1:CAS:528:DyaK3sXms1Wqt7g%3D (Pubitemid 23257823)
55. LM Hesse K Venkatakrishnan MH Court LL von Moltke SX Duan RI Shader DJ Greenblatt 2000 CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants Drug Metab Dispos 28 1176 1183 10997936 1:CAS:528:DC%2BD3cXntVSltrs%3D
56. E Higashi M Nakajima M Katoh S Tokudome T Yokoi 2007 Inhibitory effects of neurotransmitters and steroids on human CYP2A6 Drug Metab Dispos 35 508 514 17237153 1:CAS:528:DC%2BD2sXktVOntrc%3D (Pubitemid 46513276)
57. T Hiroi W Kishimoto T Chow S Imaoka T Igarashi Y Funae 2001 Progesterone oxidation by cytochrome P450 2D isoforms in the brain Endocrinology 142 3901 3908 11517168 1:CAS:528:DC%2BD3MXmsFSgs70%3D (Pubitemid 32802662)
58. N Hirota K Ito T Iwatsubo CE Green CA Tyson N Shimada H Suzuki Y Sugiyama 2001 In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans Biopharm Drug Dispos 22 53 71 11745908 1:CAS:528:DC%2BD3MXpt1Sitrc%3D (Pubitemid 34030888)
59. VM Hodges GY Molloy SN Wickramasinghe 2000 Demonstration of mRNA for five species of cytochrome P450 in human bone marrow, bone marrow-derived macrophages and human haemopoietic cell lines Br J Haematol 108 151 156 10651738 1:CAS:528:DC%2BD3cXht1altbo%3D (Pubitemid 30089947)
60. MW Hruska JA Amico TY Langaee RE Ferrell SM Fitzgerald RF Frye 2005 The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects Br J Clin Pharmacol 59 70 79 15606443 1:CAS:528:DC%2BD2MXot1WrtA%3D%3D (Pubitemid 40040098)
61. J Hukkanen P Jacob 3rd NL Benowitz 2005 Metabolism and disposition kinetics of nicotine Pharmacol Rev 57 79 115 15734728 1:CAS:528: DC%2BD2MXis1Gmtro%3D (Pubitemid 40283970)
62. C Iribarne D Picart Y Dréano F Berthou 1998 In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine Fundam Clin Pharmacol 12 194 199 9565774 1:CAS:528:DyaK1cXislenu78%3D (Pubitemid 28154609)
63. LI Kajosaari J Laitila PJ Neuvonen JT Backman 2005 Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin Basic Clin Pharmacol Toxicol 97 249 256 16176562 1:CAS:528:DC%2BD2MXhtFantb7L (Pubitemid 41433700)
64. M Katoh M Nakajima N Shimada H Yamazaki T Yokoi 2000 Inhibition of human cytochrome P450 enzymes by 1, 4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions Eur J Clin Pharmacol 55 11-12 843 852 10805063 1:CAS:528:DC%2BD3cXhslCjs7g%3D (Pubitemid 30201767)
65. KE Kenworthy JC Bloomer SE Clarke JB Houston 1999 CYP3A4 drug interactions: correlation of 10 in vitro probe substrates Br J Clin Pharmacol 48 716 727 10594474 1:CAS:528:DyaK1MXnvFSrtr8%3D (Pubitemid 29520596)
66. NL Kerry AA Somogyi F Bochner G Mikus 1994 The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes Br J Clin Pharmacol 38 243 248 7826826 1:CAS:528:DyaK2cXmsVGju70%3D (Pubitemid 24282745)
67. JW Ko Z Desta NV Soukhova T Tracy DA Flockhart 2000 In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6 Br J Clin Pharmacol 49 343 351 10759690 1:CAS:528:DC%2BD3cXjtl2hsbc%3D (Pubitemid 30195277)
68. K Kobayashi T Yamamoto K Chiba M Tani T Ishizaki Y Kuroiwa 1995 The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes Br J Clin Pharmacol 40 481 485 8703653 1:CAS:528:DyaK28XlvFaqsg%3D%3D
69. LL Koenigs RM Peter SJ Thompson AE Rettie WF Trager 1997 Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen Drug Metab Dispos 25 1407 1415 9394031 1:STN:280:DyaK1c%2FlslCnsQ%3D%3D (Pubitemid 28010927)
70. K Komatsu K Ito Y Nakajima S Kanamitsu S Imaoka Y Funae CE Green CA Tyson N Shimada Y Sugiyama 2000 Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments Drug Metab Dispos 28 475 481 10725317 1:CAS:528:DC%2BD3cXitFeqtr0%3D (Pubitemid 30185687)
71. T Kronbach D Mathys M Umeno FJ Gonzalez UA Meyer 1989 Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4 Mol Pharmacol 36 89 96 2787473 1:CAS:528:DyaL1MXlt1Kgu7g%3D (Pubitemid 19191264)
72. V Kumar DA Rock CJ Warren TS Tracy JL Wahlstrom 2006 Enzyme source effects on CYP2C9 kinetics and inhibition Drug Metab Dispos 34 1903 1908 16928789 1:CAS:528:DC%2BD28XhtFGqt7nI (Pubitemid 44771720)
73. KL Kunze WF Trager 1993 Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline Chem Res Toxicol 6 649 656 8292742 1:CAS:528:DyaK3sXlsFWmu78%3D (Pubitemid 23290017)
74. KL Kunze AC Eddy M Gibaldi WF Trager 1991 Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin Chirality 3 24 29 2039681 1:CAS:528:DyaK3MXks1Chu7k%3D
75. SS Lavhekar AK Bhopale AA Lohade EC Coutinho KR Iyer 2007 Determination of microsomal CYP2A6 activity by high performance liquid chromatography Indian J Pharm Sci 69 448 451 1:CAS:528:DC%2BD1MXhtVGqsL%2FE
76. A Le Gal Y Dréano D Lucas F Berthou 2003 Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine Toxicol Lett 144 77 91 12919726 1:CAS:528:DC%2BD3sXmt1ajsbo%3D (Pubitemid 36952612)
77. T Leemann C Transon P Dayer 1993 Cytochrome P450 TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver Life Sci 52 29 34 8417277 1:CAS:528:DyaK3sXhtFKit7Y%3D (Pubitemid 223039980)
78. XQ Li A Björkman TB Andersson M Ridderström CM Masimirembwa 2002 Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate Pharmacol Exp Ther 300 399 407 1:CAS:528:DC%2BD38Xos1ynsw%3D%3D (Pubitemid 34106229)
79. XQ Li TB Andersson M Ahlström L Weidolf 2004 Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities Drug Metab Dispos 32 821 827 15258107 1:CAS:528:DC%2BD2cXmtFCjt7Y%3D (Pubitemid 38955611)
80. AY Lu RW Wang JH Lin 2003 Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification Drug Metab Dispos 31 345 350 12642457 1:CAS:528:DC%2BD3sXisFeisbY%3D (Pubitemid 36378510)
81. D Lucas R Ferrara E Gonzalez P Bodenez A Albores M Manno F Berthou 1999 Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans Pharmacogenetics 9 377 388 10471070 1:CAS:528:DyaK1MXlsFGls7g%3D (Pubitemid 29376382)
82. E Lukkari P Taavitsainen A Juhakoski O Pelkonen 1998 Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes Pharmacol Toxicol 82 161 166 9584328 1:CAS:528:DyaK1cXisVCqurs%3D (Pubitemid 28186719)
83. B Ma T Prueksaritanont JH Lin 2000 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A Drug Metab Dispos 28 125 130 10640508 1:STN:280:DC%2BD3c7gvVyitw%3D%3D (Pubitemid 30068994)
84. J Mäenpää R Juvonen H Raunio A Rautio O Pelkonen 1994 Metabolic interactions of methoxsalen and coumarin in humans and mice Biochem Pharmacol 48 1363 1369 7945434 (Pubitemid 24318139)
85. A Mancy S Dijols S Poli P Guengerich D Mansuy 1996 Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9 Biochemistry 35 16205 16212 8973193 1:CAS:528:DyaK28XntVyisLw%3D
86. DC Mankowski 1999 The role of CYP2C19 in the metabolism of (±) bufuralol, the prototypic substrate of CYP2D6 Drug Metab Dispos 27 1024 1028 10460802 1:CAS:528:DyaK1MXlslCqsrw%3D (Pubitemid 29409638)
87. JM Margolis RS Obach 2003 Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions Drug Metab Dispos 31 606 611 12695349 1:CAS:528:DC%2BD3sXjt1Ggt7Y%3D (Pubitemid 36444170)
88. J Marill CC Capron N Idres GG Chabot 2002 Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids Biochem Pharmacol 63 933 943 11911845 1:CAS:528:DC%2BD38XitFWlsrc%3D (Pubitemid 34243006)
89. CM Masimirembwa C Otter M Berg M Jönsson B Leidvik E Jonsson T Johansson A Bäckman A Edlund TB Andersson 1999 Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research Drug Metab Dispos 27 1117 1122 10497136 1:CAS:528:DyaK1MXmtlaltbc%3D (Pubitemid 29463596)
90. S Matsumoto T Hirama T Matsubara K Nagata Y Yamazoe 2002 Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, Astemizole Drug Metab Dispos 30 1240 1245 12386130 1:CAS:528:DC%2BD38XotFyku7w%3D (Pubitemid 35265831)
91. DF McGinnity J Tucker S Trigg RJ Riley 2005 Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes Drug Metab Dispos 33 1700 1707 16081671 1:CAS:528: DC%2BD2MXhtFOru7rM (Pubitemid 41539969)
92. DF McGinnity AJ Berry JR Kenny K Grime RJ Riley 2006 Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes Drug Metab Dispos 34 1291 1300 16679385 1:CAS:528:DC%2BD28Xnslaktbk%3D (Pubitemid 44079869)
93. D McKillop MJ Wild CJ Butters C Simcock 1998 Effects of propofol on human hepatic microsomal cytochrome P450 activities Xenobiotica 28 845 853 9764927 1:CAS:528:DyaK1cXmsVOitr0%3D (Pubitemid 28446361)
94. RA McKinnon PM Hall LC Quattrochi RH Tukey ME McManus 1991 Localization of CYP1A1 and CYP1A2 mRNA in normal liver and hepatocellular carcinoma by in situ hybridization Hepatology 14 848 856 1657755 1:CAS:528:DyaK38XksVKk
95. ES Messina RF Tyndale EM Sellers 1997 A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes J Pharmacol Exp Ther 282 1608 1614 9316878 1:CAS:528:DyaK2sXmsVGlu7s%3D (Pubitemid 27408347)
96. JO Miners DJ Birkett 1996 The use of caffeine as a metabolic probe for human drug metabolizing enzymes Gen Pharmacol 27 245 249 8919637 1:CAS:528:DyaK28XisVKgtrY%3D (Pubitemid 26129183)
97. JO Miners DJ Birkett 1996 Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9 Methods Enzymol 272 139 145 8791771 1:CAS:528:DyaK28XmvFKltb0%3D (Pubitemid 26299876)
98. B Monsarrat I Royer M Wright T Cresteil 1997 Biotransformation of taxoids by human cytochromes P450: structure-activity relationship Bull Cancer 84 125 133 9180834 1:STN:280:DyaK2szisVOhuw%3D%3D (Pubitemid 27153456)
99. GC Moody SJ Griffin AN Mather DF McGinnity RJ Riley 1999 Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential Xenobiotica 29 53 75 10078840 1:CAS:528:DyaK1MXotlOjsg%3D%3D (Pubitemid 29050391)
100. L Nadin M Murray 1999 Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes Biochem Pharmacol 58 1201 1208 10484078 1:CAS:528:DyaK1MXltlymtL4%3D (Pubitemid 29381521)
101. M Nakajima T Yamamoto K Nunoya T Yokoi K Nagashima K Inoue Y Funae N Shimada T Kamataki Y Kuroiwa 1996 Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes J Pharmacol Exp Ther 277 1010 1015 8627511 1:CAS:528:DyaK28XivFehtL4%3D
102. M Nakajima M Itoh H Sakai T Fukami M Katoh H Yamazaki FF Kadlubar S Imaoka Y Funae T Yokoi 2006 CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl Int J Cancer 119 2520 2526 16988941 1:CAS:528:DC%2BD28XhtFygtbbE (Pubitemid 44691304)
103. K Nakamura T Yokoi K Inoue N Shimada N Ohashi T Kume T Kamataki 1996 CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes Pharmacogenetics 6 449 457 8946477 1:CAS:528:DyaK2sXjs1CrsA%3D%3D (Pubitemid 26380101)
104. MH Nelson AK Birnbaum RP Remmel 2001 Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors Epilepsy Res 44 71 82 11255075 1:CAS:528:DC%2BD3MXhvVagsr0%3D (Pubitemid 32209275)
105. DJ Newton RW Wang AYH Lu 1995 Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes Drug Metab Dispos 23 154 158 7720520 1:CAS:528:DyaK2MXjtVOrur4%3D
106. KK Nielsen JP Flinois P Beaune K Brøsen 1996 The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways J Pharmacol Exp Ther 277 1659 1664 8667235 1:CAS:528:DyaK28XjslGlu7w%3D (Pubitemid 27167184)
107. T Niwa T Shiraga S Yamasaki K Ishibashi Y Ohno A Kagayama 2003 In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes Xenobiotica 33 717 729 12893521 1:CAS:528: DC%2BD3sXmtVeksr4%3D (Pubitemid 36960258)
108. RS Obach 2000 Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression J Pharmacol Exp Ther 294 88 95 10871299 1:CAS:528:DC%2BD3cXksFyht7s%3D (Pubitemid 30434674)
109. BW Ogilvie D Zhang W Li D Rodrigues AE Gipson J Holsapple P Toren A Parkinson 2006 Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions Drug Metab Dispos 34 191 197 16299161 1:CAS:528: DC%2BD28XhslyitQ%3D%3D (Pubitemid 43042661)
110. OV Olesen K Linnet 2000 Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism J Clin Psychopharmacol 20 35 42 10653206 1:CAS:528: DC%2BD3cXpslSgsw%3D%3D (Pubitemid 30056351)
111. CE Ong S Coulter DJ Birkett CR Bhasker JO Miners 2000 The xenobiotic inhibitor profile of cytochrome P4502C8 Br J Clin Pharmacol 50 573 580 11136296 1:CAS:528:DC%2BD3MXkvVyqtQ%3D%3D (Pubitemid 32010017)
112. SV Otton D Wu RT Joffe SW Cheung EM Sellers 1993 Inhibition by fluoxetine of cytochrome P450 2D6 activity Clin Pharmacol Ther 53 401 409 8477556 1:CAS:528:DyaK2cXls12kurw%3D (Pubitemid 23119426)
113. SV Otton SE Ball SW Cheung T Inaba RL Rudolph EM Sellers 1996 Venlafaxine oxidation in vitro is catalysed by CYP2D6 Br J Clin Pharmacol 41 149 156 8838442 1:CAS:528:DyaK28Xhs1Oht7Y%3D (Pubitemid 26060742)
114. LP Pan P Wijnant C De Vriendt MT Rosseel FM Belpaire 1997 Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol Br J Clin Pharmacol 44 557 564 9431831 1:CAS:528:DyaK1cXjtlOgsA%3D%3D (Pubitemid 27517482)
115. O Pelkonen A Rautioa H Raunioa M Pasanen 2000 CYP2A6: a human coumarin 7-hydroxylase Toxicology 144 139 147 10781881 1:CAS:528:DC%2BD3cXisFGns7o%3D (Pubitemid 30201630)
116. MD Perloff LL von Moltke MH Court T Kotegawa RI Shader DJ Greenblatt 2000 Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms J Pharmacol Exp Ther 292 618 628 10640299 1:CAS:528:DC%2BD3cXotFemsg%3D%3D (Pubitemid 30067425)
117. ES Perloff AK Mason SS Dehal AP Blanchard L Morgan T Ho A Dandeneau RM Crocker CM Chandler N Boily CL Crespi DM Stresser 2009 Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design Xenobiotica 39 99 112 19255936 1:CAS:528:DC%2BD1MXos1agtbc%3D
118. TM Polasek JO Miners 2006 Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate Eur J Clin Pharmacol 62 203 208 16416302 1:CAS:528:DC%2BD28XitFOgsrY%3D (Pubitemid 43357578)
119. T Prueksaritanont LM Gorham B Ma L Liu X Yu JJ Zhao DE Slaughter BH Arison KP Vyas 1997 In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s Drug Metab Dispos 25 1191 1199 9321523 1:CAS:528:DyaK2sXmvVWnsb4%3D (Pubitemid 27446590)
120. T Prueksaritanont C Tang Y Qiu L Mu R Subramanian JH Lin 2002 Effects of fibrates on metabolism of statins in human hepatocytes Drug Metab Dispos 30 1280 1287 12386136 1:CAS:528:DC%2BD38XotFyku7Y%3D (Pubitemid 35265837)
121. JK Racha AE Rettie KL Kunze 1998 Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate Biochemistry 37 7407 7419 9585555 1:CAS:528:DyaK1cXislGgtLY%3D (Pubitemid 28235224)
122. A Rahman KR Korzekwa J Grogan FJ Gonzalez JW Harris 1994 Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8 Cancer Res 54 5543 5546 7923194 1:CAS:528:DyaK2cXmvFWqtLg%3D
123. BB Rasmussen TL Nielsen K Brøsen 1998 Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro Eur J Clin Pharmacol 54 9-10 735 740 9923577 1:STN:280:DyaK1M7itVCmsA%3D%3D (Pubitemid 29024207)
124. S Rendic 2002 Summary of information on human CYP enzymes: human P450 metabolism data Drug Metab Rev 34 83 448 11996015 1:CAS:528:DC%2BD38Xjs1KgsLY%3D (Pubitemid 34311090)
125. AE Rettie KR Korzekwa KL Kunze RF Lawrence AC Eddy T Aoyama HV Gelboin FJ Gonzalez WF Trager 1992 Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions Chem Res Toxicol 5 54 59 1581537 1:CAS:528:DyaK38Xjtl2msw%3D%3D
126. T Richter TE Mürdter G Heinkele J Pleiss S Tatzel M Schwab M Eichelbaum UM Zanger 2004 Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine J Pharmacol Exp Ther 308 189 197 14563790 1:CAS:528:DC%2BD2cXmsFegsg%3D%3D (Pubitemid 38090717)
127. BJ Ring SN Binkley M Vandenbranden SA Wrighton 1996 In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A Br J Clin Pharmacol 41 181 186 8866916 1:CAS:528:DyaK28XitlGlur8%3D
128. B Rochat JM Morsman GI Murray WD Figg HL McLeod 2001 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296 537 541 11160641 1:CAS:528:DC%2BD3MXoslejtQ%3D%3D (Pubitemid 32112483)
129. AD Rodrigues BW Surber Y Yao SL Wong EM Roberts 1997 [O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes Drug Metab Dispos 25 1097 1100 9311627 1:CAS:528:DyaK2sXmt1Wqtrg%3D (Pubitemid 27396499)
130. J Sahi CB Black GA Hamilton X Zheng S Jolley KA Rose D Gilbert EL LeCluyse MW Sinz 2003 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition Drug Metab Dispos 31 439 446 12642470 1:CAS:528:DC%2BD3sXisFeit78%3D (Pubitemid 36378521)
131. Y Sai R Dai TJ Yang KW Krausz FJ Gonzalez HV Gelboin M Shou 2000 Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450 Xenobiotica 30 327 343 10821163 1:CAS:528:DC%2BD3cXmtFygtb8%3D (Pubitemid 30251243)
132. M Salsali A Holt GB Baker 2004 Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6 Cell Mol Neurobiol 24 63 76 15049511 1:CAS:528: DC%2BD2cXlt1egtg%3D%3D (Pubitemid 38233730)
133. J Schmider DJ Greenblatt LL von Moltke JS Harmatz RI Shader 1995 N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors J Pharmacol Exp Ther 275 592 597 7473143 1:CAS:528:DyaK2MXpsF2htbk%3D (Pubitemid 26025547)
134. J Schmider DJ Greenblatt SM Fogelman LL von Moltke RI Shader 1997 Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1 Biopharm Drug Dispos 18 227 240 9113345 1:CAS:528:DyaK2sXis1KgurY%3D (Pubitemid 27191803)
135. D Schwarz P Kisselev I Roots 2005 CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin Eur J Cancer 41 151 158 15618000 1:CAS:528:DC%2BD2MXhtVGiuw%3D%3D (Pubitemid 40029668)
136. H Schweikl JA Taylor S Kitareewan P Linko D Nagorney JA Goldstein 1993 Expression of CYP1A1 and CYP1A2 genes in human liver Pharmacogenetics 3 239 249 8287062 1:CAS:528:DyaK2cXhsF2ktrs%3D (Pubitemid 23333093)
137. C Senda W Kishimoto K Sakai A Nagakura T Igarashi 1997 Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam Xenobiotica 27 913 922 9381732 1:CAS:528:DyaK2sXmtlShtbY%3D (Pubitemid 27394324)
138. M Shou AY Lu 2009 Antibodies as a probe in cytochrome P450 research Drug Metab Dispos 37 925 931 19196844 1:CAS:528:DC%2BD1MXlsVWitL8%3D
139. E Skjelbo K Brøsen 1992 Inhibitors of imipramine metabolism by human liver microsomes Br J Clin Pharmacol 34 256 261 1389950 1:CAS:528:DyaK38Xmt1Glur0%3D
140. MG Soars K Grime RJ Riley 2006 Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5 Xenobiotica 36 287 299 16684709 1:CAS:528:DC%2BD28XksVGmsro%3D
141. JC Stevens RB White SH Hsu M Martinet 1997 Human liver CYP2B6-catalyzed hydroxylation of RP 73401 J Pharmacol Exp Ther 282 1389 1395 9316851 1:CAS:528:DyaK2sXmsVGltLY%3D (Pubitemid 27408320)
142. DM Stresser MI Broudy T Ho CE Cargill AP Blanchard R Sharma AA Dandeneau JJ Goodwin SD Turner JC Erve CJ Patten SS Dehal CL Crespi 2004 Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible Drug Metab Dispos 32 105 112 14709627 1:CAS:528: DC%2BD2cXnsFWqs7o%3D (Pubitemid 38112542)
143. H Suzuki MB Kneller RL Haining WF Trager AE Rettie 2002 (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19 Drug Metab Dispos 30 235 239 11854139 1:CAS:528:DC%2BD38Xhtl2qtrs%3D (Pubitemid 34175012)
144. P Taavitsainen M Anttila L Nyman H Karnani JS Salonen O Pelkonen 2000 Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes Pharmacol Toxicol 86 215 221 10862503 1:CAS:528:DC%2BD3cXjs1Ggtr8%3D (Pubitemid 30333648)
145. P Taavitsainen R Juvonen O Pelkonen 2001 In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene Drug Metab Dispos 29 217 222 11181487 1:CAS:528: DC%2BD3MXhsVKit7c%3D (Pubitemid 32179519)
146. BK Tang W Kalow 1996 Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans Methods Enzymol 272 124 131 8791769 1:CAS:528: DyaK28XmvFKltb8%3D (Pubitemid 26299874)
147. W Tang RW Wang AY Lu 2005 Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective Curr Drug Metab 6 503 517 16248842 1:CAS:528:DC%2BD2MXhtVWku7vO (Pubitemid 41300795)
148. SA Testino Jr G Patonay 2003 High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry J Pharm Biomed Anal 30 1459 1467 12467917 1:CAS:528:DC%2BD38XptFKhsLw%3D (Pubitemid 35435339)
149. A Tornio M Niemi PJ Neuvonen JT Backman 2008 Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone Drug Metab Dispos 36 73 80 17913794 1:CAS:528: DC%2BD1cXmtFGksw%3D%3D
150. RA Totah P Sheffels T Roberts D Whittington K Thummel ED Kharasch 2008 Role of CYP2B6 in stereoselective human methadone metabolism Anesthesiology 108 351 352
151. TS Tracy KR Korzekwa FJ Gonzalez IW Wainer 1999 Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil Br J Clin Pharmacol 47 545 552 10336579 1:CAS:528:DyaK1MXjsFejs70%3D (Pubitemid 29199727)
152. TH Tran LL von Moltke K Venkatakrishnan BW Granda MA Gibb RS Obach JS Harmatz DJ Greenblatt 2002 Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors Drug Metab Dispos 30 1441 1445 12433817 1:CAS:528:DC%2BD38XptVyisLY%3D (Pubitemid 35397052)
153. GT Tucker JB Houston SM Huang 2001 Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus Clin Pharmacol Ther 70 103 114 11503003 1:STN:280: DC%2BD3MvotFOjsw%3D%3D (Pubitemid 32777761)
154. M Turpeinen R Nieminen T Juntunen P Taavitsainen H Raunio O Pelkonen 2004 Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro Drug Metab Dispos 32 626 631 15155554 1:CAS:528: DC%2BD2cXktlOgtrk%3D (Pubitemid 38668155)
155. M Turpeinen H Raunio O Pelkonen 2006 The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico Curr Drug Metab 7 705 714 17073575 1:CAS:528:DC%2BD28XhtVWgt7rE (Pubitemid 44509677)
156. K Venkatakrishnan LL von Moltke SX Duan JC Fleishaker RI Shader DJ Greenblatt 1998 Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man J Pharm Pharmacol 50 265 274 9600717 1:CAS:528:DyaK1cXitlKitb8%3D (Pubitemid 28143594)
157. K Venkatakrishnan LL von Moltke DJ Greenblatt 1998 Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity J Pharm Sci 87 1502 1507 10189256 1:CAS:528:DyaK1cXmslyiu7g%3D
158. LL von Moltke DJ Greenblatt MM Cotreau-Bibbo JS Harmatz RI Shader 1994 Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake- inhibitor antidepressants, ketoconazole and quinidine Br J Clin Pharmacol 38 23 31 1:CAS:528:DyaK2cXmt1Squ7k%3D (Pubitemid 24222832)
159. LL von Moltke DJ Greenblatt MM Cotreau-Bibbo SX Duan JS Harmatz RI Shader 1994 Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake- inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo J Pharmacol Exp Ther 268 1278 1283 (Pubitemid 24100342)
160. LL von Moltke DJ Greenblatt MH Court SX Duan JS Harmatz RI Shader 1995 Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants J Clin Psychopharmacol 15 125 131
161. LL von Moltke DJ Greenblatt SX Duan J Schmider L Kudchadker SM Fogelman JS Harmatz RI Shader 1996 Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine Psychopharmacology (Berl) 128 398 407 (Pubitemid 26417681)
162. LL von Moltke DJ Greenblatt SX Duan JS Harmatz CE Wright RI Shader 1996 Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo J Clin Psychopharmacol 16 104 112
163. LL von Moltke DJ Greenblatt JS Harmatz SX Duan LM Harrel MM Cotreau-Bibbo GA Pritchard CE Wright RI Shader 1996 Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole J Pharmacol Exp Ther 276 370 379 (Pubitemid 126660470)
164. LL von Moltke DJ Greenblatt J Schmider SX Duan CE Wright JS Harmatz RI Shader 1996 Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents J Clin Pharmacol 36 783 791 (Pubitemid 26329500)
165. LL von Moltke SX Duan DJ Greenblatt SM Fogelman J Schmider JS Harmatz RI Shader 1997 Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms Biol Psychiatry 41 377 380 (Pubitemid 27095264)
166. LL von Moltke DJ Greenblatt SX Duan J Schmider CE Wright JS Harmatz RI Shader 1997 Human cytochromes mediating N-demethylation of fluoxetine in vitro Psychopharmacology (Berl) 132 402 407 (Pubitemid 27373483)
167. LL von Moltke DJ Greenblatt JM Grassi BW Granda SX Duan SM Fogelman JP Daily JS Harmatz RI Shader 1998 Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir J Clin Pharmacol 38 106 111 (Pubitemid 28117365)
168. LL von Moltke DJ Greenblatt BW Granda JM Grassi J Schmider JS Harmatz RI Shader 1999 Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions Psychopharmacology (Berl) 145 113 122 (Pubitemid 29339770)
169. RL Walsky RS Obach 2004 Validated assays for human cytochrome P450 activities Drug Metab Dispos 32 647 660 15155557 1:CAS:528:DC%2BD2cXktlOgt74%3D (Pubitemid 38668158)
170. RL Walsky RS Obach 2007 A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1, 1′, 1″-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6 Drug Metab Dispos 35 2053 2059 17682072 1:CAS:528:DC%2BD2sXht1Cnu7jN (Pubitemid 350005195)
171. RL Walsky RS Obach EA Gaman JP Gleeson WR Proctor 2005 Selective inhibition of human cytochrome P4502C8 by montelukast Drug Metab Dispos 33 413 418 15608135 1:CAS:528:DC%2BD2MXisFSgtro%3D (Pubitemid 40279942)
172. RL Walsky EA Gaman RS Obach 2005 Examination of 209 drugs for inhibition of cytochrome P450 2C8 J Clin Pharmacol 45 68 78 15601807 1:CAS:528: DC%2BD2MXks1Sls7k%3D
173. RL Walsky AV Astuccio RS Obach 2006 Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6 J Clin Pharmacol 46 1426 1438 17101742 1:CAS:528:DC%2BD28XhtlajsbvL (Pubitemid 44704203)
174. C Wandel RB Kim FP Guengerich AJ Wood 2000 Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro Drug Metab Dispos 28 895 898 10901697 1:CAS:528:DC%2BD3cXlt1ahtrw%3D (Pubitemid 30612606)
175. H Wang LM Tompkins 2008 CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme Curr Drug Metab 9 598 610 18781911 1:CAS:528:DC%2BD1cXht1ynsbjP
176. RW Wang DJ Newton TD Scheri AY Lu 1997 Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis Drug Metab Dispos 25 502 507 9107550 1:CAS:528:DyaK2sXivVens78%3D (Pubitemid 27209375)
177. JS Wang M Neuvonen X Wen JT Backman PJ Neuvonen 2002 Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes Drug Metab Dispos 30 1352 1356 12433802 (Pubitemid 35397037)
178. BA Ward JC Gorski DR Jones SD Hall DA Flockhart Z Desta 2003 The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity J Pharmacol Exp Ther 306 287 300 12676886 1:CAS:528:DC%2BD3sXkvF2ksr8%3D (Pubitemid 36734384)
179. X Wen JS Wang JT Backman KT Kivistö PJ Neuvonen 2001 Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9 Drug Metab Dispos 29 1359 1361 11602509 1:CAS:528:DC%2BD3MXnsl2ku7k%3D (Pubitemid 33000680)
180. X Wen JS Wang JT Backman J Laitila PJ Neuvonen 2002 Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively Drug Metab Dispos 30 631 635 12019187 1:CAS:528:DC%2BD38XktFSlsLk%3D (Pubitemid 34579094)
181. LC Wienkers CJ Wurden E Storch KL Kunze AE Rettie WF Trager 1996 Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19 Drug Metab Dispos 24 610 614 8723744 1:CAS:528:DyaK28XivVOmsr8%3D (Pubitemid 26146703)
182. JA Williams I Susan SI Hurst J Bauman BC Jones R Hyland JP Gibbs RS Obach SE Ball 2003 Reaction phenotyping in drug discovery: moving forward with confidence? Curr Drug Metab 4 527 534 14683480 1:CAS:528:DC%2BD3sXpslShtLc%3D (Pubitemid 37536873)
183. SA Wrighton BJ Ring 1994 Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine Pharm Res 11 921 924 7937537 1:CAS:528:DyaK2cXls12lsrY%3D (Pubitemid 24210633)
184. Wrighton SA, Thummel KE (2000) CYP3A. In: Levy RH (ed) Metabolic drug interactions. Lippincott, Williams and Wilkins, Philadelphia, pp 115-133
185. H Yamazaki T Shimada 1997 Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers Biochem Pharmacol 54 1195 1203 9416970 1:CAS:528:DyaK2sXnsFamu7k%3D (Pubitemid 27497246)
186. JK Yano TT Denton MA Cerny X Zhang EF Johnson JR Cashman 2006 Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization J Med Chem 49 6987 7001 17125252 1:CAS:528:DC%2BD28XhtFKrs7bF (Pubitemid 44885987)
187. H Yin J Racha SY Li N Olejnik H Satoh D Moore 2000 Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation Xenobiotica 30 141 154 10718122 1:CAS:528:DC%2BD3cXjs1Ghsr4%3D (Pubitemid 30125115)
188. Zanger UM, Eichelbaum M (2000) CYP2D6. In: Levy RH (ed) Metabolic drug interactions. Lippincott Williams and Wilkins, Philadelphia, pp 87-94
189. Z Zhang MJ Fasco Z Huang FP Guengerich LS Kaminsky 1995 Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe Drug Metab Dispos 23 1339 1346 8689941 1:CAS:528:DyaK28XhvF2guw%3D%3D
190. W Zhang T Kilicarslan RF Tyndale EM Sellers 2001 Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro Drug Metab Dispos 29 897 902 11353760 1:CAS:528: DC%2BD3MXjvFantrc%3D (Pubitemid 32488648)
191. P Zhao KL Kunze CA Lee 2005 Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes Drug Metab Dispos 33 853 861 15743977 1:CAS:528:DC%2BD2MXksleks7g%3D (Pubitemid 40686640)
192. S Zhou JW Paxton MD Tingle P Kestell 2000 Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5, 6-dimethylxanthenone-4-acetic acid Drug Metab Dispos 28 1449 1459 11095582 1:CAS:528:DC%2BD3cXos1SrsrY%3D
193. L Zou MR Harkey GL Henderson 2002 Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity Life Sci 71 1579 1589 12127912 1:CAS:528:DC%2BD38XlsVerur4%3D (Pubitemid 34808718)